Health Care Slips as XLV Faces Weak Breadth and Rising Yields

The Health Care sector closed -0.3% on Tuesday, September 29, weighed down by narrow participation across the group as only 32.2% of its S&P 500 members posted gains. The sector exchange-traded fund, Health Care Select Sector SPDR Fund (XLV), mirrored that session move at -0.3% to finish at $170.73. The fractional pullback unfolded against a broader market backdrop where only 3 of the 11 sectors rose, as rising Treasury yields pressured equity valuations and kept major indexes under modest selling pressure.

Individual performance across the sector remained subdued. Medtronic PLC landed at the bottom of the group at -2.7%, while gains were led by Moderna Inc at +3.1% and Cardinal Health Inc at +1.6%. Company-specific announcements did little to alter the sector's trajectory. AbbVie announced that it secured regulatory approval for its once-daily Parkinson's treatment with availability expected in October. In biopharma dealmaking, Novo Nordisk agreed to acquire rights to an oral obesity drug candidate for up to $2.6 billion.

The cap-weighted sector move of -0.3% closely tracked the equal-weighted return of -0.2%, indicating that selling was evenly distributed across large and smaller constituents alike. EasyAlpha grades the stocks in the sector against their industry peers. Companies graded A or B have stronger fundamentals, and historically they have carried a lower risk of large drawdowns than companies graded D or E. Currently, 52.9% of the fund's graded holdings sits in those top two tiers, providing an underlying base of fundamental quality even as short-term momentum stalls.

Over longer horizons, XLV retains solid gains, showing +18.0% over the past 100 sessions and +25.6% over the past twelve months, despite closing the past month at -0.3%. That extended strength reflects how larger pharmaceutical and medical device holdings have held up through broader market fluctuations.